



Letter of Support for the CBTTC/PNOC NIH Pediatric Brain SPORE Grant FAQ

- 1. To whom should I address the letter?
 - a. Please address the letter to Adam Resnick Ph.D. and Michael Prados MD

Adam Resnick PhD Center for Data-Driven Discovery in Biomedicine Children's Hospital of Philadelphia 3501 Civic Center Boulevard Philadelphia, PA 19104

Michael Prados MD University of California San Francisco 1450 3rd Street San Francisco, CA, 94158-0520

- 2. Should I mail the letter?
 - a. If possible, please email the letter as a .pdf file to Jena Lilly <u>lillyj@email.chop.edu</u> and Ryan Velasco <u>velascor@email.chop.edu</u>. If that is an issue, you can email an MS Word (or other .doc format) file and the team at CBTTC will assist you.
- 3. What are the important points to highlight:
 - a. Your personal narrative, and why you would support this application.
 - b. That there has never been a pediatric brain tumor SPORE grant, which is crucial to driving clinical translational research on behalf of children with brain tumors.
 - c. Brain tumors are the leading cause of cancer-related death in children in the U.S. and a leading cause of cancer-related death in children globally.
 - d. Due to the nature of pediatric brain tumors, this proposal MUST include collaborative efforts, as no one institution sees enough pediatric brain tumors in a year to drive research.
 - i. SPORE grants are normally given to a single institution. We need to strongly clarify why that can't be the case for this SPORE. To ensure the success of this grant, as we will indicate multiple collaborative efforts across several institutions.
 - e. That PNOC and CBTTC have been successful programs, with a key part of this success due to CBTTC and PNOC having worked together very closely over the past decade and involving first-in-kind national and global partnerships across institutions.
 - f. If you have been supporters, or have appreciated the work of PNOC and CBTTC, please indicate that.
- 4. When do you need the letter?
 - a. If possible, we would love to have the letters in .pdf format emailed to us by the end of March 2020.
- 5. Should I use letterhead, and from whom should it be signed?
 - a. Yes, please use letterhead and have it signed by the president of your organization/foundation, key leadership, or of course yourself if coming as a personal letter.





- 6. Who should I contact with questions?
 - a. Please contact Jena Lilly, <u>lilly@email.chop.edu</u> and Ryan Velasco <u>velascor@email.chop.edu</u> with any questions. Please use the subject line: Pediatric Brain Tumor SPORE LOS

Background:

PNOC: has launched 18 innovative clinical trials for children with brain tumors and has 19 member institutions. PNOC has fostered its growth to currently include 19 academic centers across the United States, with international sites in Canada, Australia, Europe, and soon-to-open sites in India and Israel. (PNOC, https://pnoc.us)

CBTTC: CBTTC has become the largest biorepository of its kind with 17 members across the U.S. and International landscape, linking longitudinally clinically annotated biospecimens including radiological and pathology imaging and genomic data for thousands of children with brain cancer. The CBTTC data centers offer a rich environment for basic and translational research with both patient samples and animal models extensively profiled and available for use for investigators around the globe. (CBTTC, https://cbttc.org)

Analytic tools: Tools include the NIH Gabriella Miller Kids First Data Resources Center (<u>https://kidsfirstdrc.org/</u>), CAVATICA (cavatica,.org), PedcBioPortal (<u>http://pedcbioportal.org/#</u>), which provide the unique opportunity in the context of a SPORE to translate these big data resources for clinical impact.